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http://dx.doi.org/10.1016/j.jacl.2015.0BACKGROUND: Apolipoprotein CIII (apoC-III) is an atherogenic protein found on HDL, VLDL
and LDL.
OBJECTIVE: The objective of this study is to review the literature on the association of blood apoC-
III level with cardiovascular events and the dose-response relationship for this association.
METHODS AND RESULTS: MEDLINE, EMBASE, BIOSIS, CINAHL, Clinicaltrials.gov, grey-
literature sources, contact with investigators, and reference lists of studies, without language restric-
tions, were reviewed. Twelve studies (5 retrospective and 7 prospective) with a total of 3163 cases
of cardiovascular events met inclusion criteria for this systematic review. The pooled standardized
mean difference showed significantly higher levels of apoC-III in the non-HDL fraction of plasma (rep-
resenting apoC-III in VLDL and LDL) in those with cardiovascular disease compared with controls;
no difference for apoC-III levels in HDL; and, a trend toward higher total plasma apoC-III in the
cases. Pooled risk estimates from the meta-analysis were 2.48 (1.48–4.32; non-HDL apoC-III), 1.09
(0.65–1.82; HDL apoC-III), and 1.33 (1.07–1.66; total apoC-III) for a cardiovascular event with a
5-mg/dL increase in apoC-III.
CONCLUSIONS: The current body of literature includes several methodologically sound studies that
together provide consistent evidence for an association of cardiovascular events with blood apoC-III
level in total plasma or in VLDL and LDL. More data are needed to determine importance of levels
of apoC-III in specific lipoproteins for cardiovascular risk assessment and management and to elucidate
the interaction between triglycerides and apoC-III in relation to risk of cardiovascular disease.
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5.002Introduction
Apolipoprotein (Apo) CIII is a small 8.8-kDa apolipo-
protein, which is synthesized mainly in the liver. It resides
on the surface of very low–density lipoproteins (VLDLs),
low-density lipoproteins (LDLs), and on high-densitynder the CC BY-NC-ND license (http://creativecommons.org/licenses/
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plasma lipoprotein metabolism and lead to hypertriglycer-
idemia. ApoC-III dampens clearance of apoB lipoproteins
from the circulation by interfering with their binding to
hepatic apoB/E receptors,1,2 and this is its most well-
established property, supported by transgenic mouse exper-
iments3–5 and human lipoprotein metabolism.6–8 Inhibition
of VLDL clearance by apoC-III leads to hypertriglyceride-
mia and the formation of LDL, especially small, dense
LDL.6–8 Second, apoC-III at high concentrations inhibits
the action of lipoprotein lipase to hydrolyze lipoprotein tri-
glyceride (TG), in vitro.9,10 However, experiments that
overexpressed apoC-III in mice at low levels do not show
inhibition of TG lipolysis.3–5 Studies of human lipoprotein
metabolism do not show a reduced rate of lipolytic conver-
sion of larger to smaller VLDLs that contain high amounts
of apoC-III compared with VLDLs without apoC-III.6–8
Third, it has been shown recently that apoC-III assists in
the formation of TG-rich VLDL in liver cells, stimulating
the secretion of VLDL.11 These findings are supporting ev-
idence that apoC-III secretion into the circulation is
strongly correlated with hypertriglyceridemia in hu-
mans.6,7,12,13 Human studies have also suggested that the
effects of apoC-III are in part associated with reduction
in the lipoprotein concentration of apoE, the usual ligand
for lipid uptake of TG-rich lipoproteins. Yet, further evi-
dence regarding this mechanism suggests that even with
loss of apoE, apoC-III overexpression leads to a marked hy-
pertriglyceridemia likely secondary to defective lipolysis of
TG-rich lipoproteins in vivo.14 This is also supported by the
finding that individuals with an apoC-III deficiency demon-
strate a significantly increased clearance of VLDL.15
Besides its effect on lipoprotein metabolism, apoC-III
has direct atherogenic properties by stimulating the adhe-
sion of blood monocytes to endothelial cells and inducing
the production of inflammatory mediators in these
cells.16,17 ApoC-III as a component of LDL increases the
binding of LDL to vascular proteoglycan potentially
enhancing LDL retention in the arterial wall.18
Given the multiple atherogenic effects of apoC-III
identified in basic research, clinical research has also found
apoC-III to be a potential cardiovascular risk factor.19–25
ApoC-III level has been correlated with insulin resistance,
obesity, and hypertriglyceridemia.26 ApoB lipoproteins
with apoC-III appear to augment risk out of proportion to
their low concentration in the plasma.19,21 This hypothesis
is supported by the observation that humans with genetic
deficiency of apoC-III have lower TG and decreased LDL
cholesterol levels as well as reduced atherosclerosis.27 In
addition, an extensive body of literature suggests an associ-
ation of certain apoC-III polymorphisms with an increased
risk for cardiovascular events.28–31 However, to this point,
only a limited number of studies investigated the asso-
ciation of blood apoC-III with cardiovascular disease
(CVD) end points such as myocardial infarction (MI) or
stroke.20,21,25,32–35The goal of this study was to systematically review
current literature to determine the association of serum or
plasma apoC-III levels and CVD events.Materials and methods
The Meta-analysis Of Observational Studies in Epide-
miology guidelines and the Preferred Reporting Items for
Systematic Reviews and Meta-Analyses statement were
used as reference for all stages of design, implementation,
and reporting of this systematic review.36,37
Identification of publications
We performed a search for all prospective and retro-
spective observational studies (case–control and cohort
studies) and clinical trials measuring blood level of
apoC-III and assessing cardiovascular outcomes by using
computerized literature searches for publications, by scan-
ning references of retrieved articles, and by contacting
experts on lipid metabolism and cardiovascular epi-
demiology. Our online literature search encompassed
MEDLINE, EMBASE, BIOSIS, CINAHL, SCOPUS/
SciVerse, the Cochrane library, Clinicaltrials.gov, and
grey-literature sources (a system for information on grey
literature in Europe, a British library inside database, and
dissertation abstracts online). We also hand-searched the
reference lists of identified studies. For each database, the
years searched included the earliest available online year
of indexing throughout February 2015. Our MEDLINE
search terms were (‘‘Apolipoprotein C-III’’ [Mesh] OR
‘‘Apolipoprotein C-III’’ [tiab]) AND (‘‘cardiovascular dis-
eases’’ [Mesh] OR ‘‘cardiovascular disease’’ [tiab] OR
‘‘cardiovascular diseases’’ [tiab] OR ‘‘heart disease’’
[tiab] OR ‘‘heart diseases’’ [tiab] OR ‘‘myocardial infarc-
tion’’ [tiab] OR ‘‘myocardial infarctions’’ [tiab] OR ‘‘heart
attack’’ [tiab] OR ‘‘heart attacks’’ [tiab] OR ‘‘sudden
death’’ [tiab] OR ‘‘sudden deaths’’ [tiab] OR ‘‘stroke’’
[tiab] OR ‘‘strokes’’ [tiab] OR ‘‘cerebrovascular accident’’
[tiab] OR ‘‘cerebrovascular accidents’’[tiab]) NOT (‘‘Case
Reports’’[Publication Type]). All searches were performed
without language restriction. All reviewed articles were
maintained as part of the study protocol, and any reason
for exclusion from analysis was documented.
Inclusion criteria
Studies were included in this systematic review if they
measured apoC-III blood levels (serum or plasma) at least
once during the study and if one or more of coronary heart
disease (CHD), MI, stroke, and sudden death from either
CHD or stroke was assessed as an outcome. Ecologic and
a priori cross-sectional studies and studies that measured
the expression of specific apoC-III polymorphisms only
but not plasma level of apoC-III, and general reviews,
500 Journal of Clinical Lipidology, Vol 9, No 4, August 2015commentaries, or case reports were searched for relevant
references, but not included in this study. When multiple
reports of a single trial or observational study were
published, we reviewed all reports to obtain the most
complete information and included each study only once.
To be included in the analysis, case–control studies had to
define the criteria for selecting cases and controls. A total
number of 1357 titles and abstracts retrieved from online
databases were reviewed to find potentially eligible
studies. We examined 61 studies in detail independently
and in duplicate to determine inclusion and/or exclusion
criteria and identified 12 studies that were included in the
analysis (Fig. 1). Forty-nine studies were excluded
because they were reviews, commentaries, letters, or
cross-sectional studies (n 5 10); reported only genotype
expression but no plasma and/or serum level of apoC-III
in cases, controls, or both groups (n 5 15); and did not
assess CHD, MI, stroke, and sudden cardiac death (SCD)
as an outcome (n 5 19). Five articles were reviewed for
the most accurate information but excluded as duplicate
reports of already included studies.
Data extraction
We assembled the following information for each study:
year of publication, location of study, study design, age
range of study population, number of patients enrolled,Figure 1 Screening and selection of identified studies. Exposure and/o
phenotype or other aspects of apoC-III, but did not measure concentra
criteria not met suggests that coronary heart disease (CHD), myocardi
were not assessed; Duplicate report suggests that data from same poputotal apoC-III and apoC-III on specific lipoproteins if
measured, outcomes (CHD, MI, stroke, SCD, or cerebro-
vascular death) that were assessed, and relative risk
estimates where available. The level of adjustment for
cofounders of any estimates was also recorded. Several
studies measured apoC-III levels weeks to months after the
outcome occurred instead of pre-event levels of exposure.
For the purpose of this review, these studies will be termed
as retrospective studies. Two readers independently ex-
tracted the data (M.W.v.B. and B.H.), with review by a third
investigator (F.M.S.).
Statistical methods
Of each publication, the effect estimates from the main
multivariable model with the greatest degree of adjustment
for confounders was used for the meta-analysis. Given the
small number of studies, no subgroup analyses or tests for
publication bias were performed. The dose–response meta-
analyses were performed using generalized least-square
method for trend estimation of summarized dose–response
based on the Greenland and Longnecker method.38
Restricted cubic splines were used to assess for potential
nonlinear relations between apoC-III and cardiovascular
events. Pooled effect sizes were calculated using DerSimo-
nian and Laird random-effects models,39 and forest plots
were created for the association of total plasma apoC-III,r outcome criteria not met suggests that studies assessed apoC-III
tion in plasma and/or serum in cases, controls, or both. Outcome
al infarction, stroke, or sudden death from either CHD or stroke
lation are presented and included with previous publication.
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and cardiovascular events using the METAN command.
Between-study heterogeneity was assessed by the I2 statis-
tic.40 All statistical tests were conducted using STATA
version 11.0 (StataCorp, College Station, TX) and were
2-sided with an alpha 5 0.05.
Results
The main characteristics of the 12 studies included in
this review and important limitations are shown in Table 1.
Five reports were from retrospective studies including pa-
tients with angina pectoris (n 5 1), coronary artery disease
(CAD; n 5 3), and/or MI (n 5 3) as the outcome of inter-
est.23,25,34,35,41 The remaining 8 studies included in this
review were prospective studies investigating angina pecto-
ris (n5 2), CAD (n5 1), MI (n5 4), recurrent MI (n5 1),
SCD (n 5 1), stroke (n 5 2), coronary death (n 5 3),
and/or total cardiovascular mortality (n 5 3) as the out-
comes.20–22,24,32,33,42
Among included studies, apoC-III levels were measured
in various types of samples (Table 2), including total
plasma or serum apoC-III (n 5 10),21–25,33–35,41,42 apoC-
III on non-HDL lipoproteins (n 5 5),20,21,23,25,35 or apoC-
III on HDL (n 5 5).20,23,25,32,35 Most reviewed studies
reported the concentration of apoC-III in subjects with
and without CVD for either total blood apoC-III and/or at
least one of the apoC-III–containing lipoprotein fractions.
Four studies simply compared plasma or serum levels of
cases and controls, but calculated no measure of association
for total apoC-III or a fraction thereof.33–35,41
Eight studies reported adjusted risk estimates for the
association of apoC-III levels and the cardiovascular
outcome under investigation (Table 3).20–25,32,42
Data from studies comparing plasma or serum
concentration of apoC-III
Four studies included in this review primarily
compared apoC-III level of cases and controls33–35,41;
measured levels of total apoC-III or one of the subfrac-
tions in subjects with and without CVD were available
for 11 studies. The technique for exposure assessment
in all these studies was relatively consistent. The
pooled standardized mean difference in total apoC-III
was 20.16 standard deviation (SD; 20.36, 0.04; P 5
.124), HDL apoC-III 0.0 SD (20.10, 0.09; P 5 .96),
and non-HDL apoC-III 20.28 SD (20.39, 20.16;
P , .001), providing evidence for consistently lower
levels of non-HDL apoC-III in controls compared with
subjects with CVD (Fig. 2).
Effect estimates for apoC-III in total plasma,
non-HDL, and HDL
Of the 12 studies, 8 reported effect estimates for the
association of apoC-III and cardiovascular events.20–25,32,42Olivieri et al and the TG and HDL Working Group likely
used the same cohort from the Verona Heart Study to calcu-
late relative risk estimates for the association of plasma
apoC-III and cardiovascular events.22,42 The TG and HDL
Working Group publication used a slightly larger sample
size, longer follow-up, and higher degree of adjustment
for covariates in their statistical models and was therefore
chosen for inclusion in the meta-analysis (Table 3).42
In a retrospective case–control study, Gerber et al
investigated 90 consecutive patients with CHD and
compared them with 209 hospital-based controls.25 Serum
concentrations of apoC-III were measured, and MI or
CAD was the outcome of interest. In this study, the authors
found an odds ratio for a cardiovascular event of 1.82
(1.18–2.79) with each SD increase in total serum apoC-
III, a 2.44 (1.58–3.78)/1-SD increase in odds for non-
HDL apoC-III, and a decreased odds of MI or CAD of
0.64 (0.42–0.96)/1 SD for HDL apoC-III.25 This study
has several methodological limitations including the
contemporary assessment of exposure and outcome.
In the Turkish Adult Risk Factor cohort study Onat et al
report an odds ratio (comparing the highest to the lowest
quartile) for the association of total apoC-III and CAD of
3.88 (1.32–11.4; men) and 2.54 (1.0–6.42; women); HDL
apoC-III and CAD, 2.70 (1.0–7.25; men) and 2.57
(0.94–7.01; women); and non-HDL apoC-III and CAD,
8.87 (2.46–29.8; men) and 3.22 (1.29–8.01; women).23 The
study population of this study consisted of 857 unselected
participants of the representative population sample of the
Turkish Adult Risk Factor Survey, aged 33 to 82 years, hav-
ing a mean waist circumference of 89.4 and 92.9 cm,
respectively, 42% of whom had the metabolic syndrome.
Limitations of this study include that apoC-III was only
measured once, and likely at the time of assessment of
the outcome as well as limited adjustment for confounders
in the analysis.
In a nested case–control study of the Cholesterol and
Recurrent Events trial Sacks et al demonstrated a monot-
onous, graded increase in relative risk of recurrent MI or
SCD of 2.25 (1.4–3.6) between the highest quintile of
non-HDL apoC-III and the lowest quintile in the study
population.20 This association remained significant after
adjustment for TGs, LDL, and HDL. The highest quintile
of HDL apoC-III carried an excess risk of 1.28 (0.8–2.0)
in the same study.20 The Cholesterol and Recurrent Events
trial was a randomized placebo-controlled trial of pravasta-
tin in 4159 patients with MI and average LDL choles-
terol concentrations at baseline (115–174 mg/dL; mean,
139 mg/dL). Baseline concentrations of VLDL–apolipopro-
tein (apo) B (the VLDL particle concentration), VLDL
lipids, and apoC-III or apoE in VLDL 1 LDL and in
HDL were compared in patients who had either a MI or
coronary death (cases, n 5 418) with those in patients
who did not have a cardiovascular event (control subjects,
n 5 370) in 5 years of follow-up.
In an analysis of participants of the population-based
cohort study on glucose metabolism and diabetes
Table 1 Main characteristics of included studies
Author, year,
reference Country Study design
Total no.
of subjects
# of
cases
Follow-
up time
Age of
cases, y
Male
(%)
ApoC-III
measurement(s) Outcome
End point
assessment Limitations
Genest et al,
199141
USA Retrospective
case–control
study
281 145 N/A 51.0 6 7.0 100 Plasma apo-CIII CAD Cases, CA,
controls, PMH
Ambiguous ascertainment of
end point*/comparison of
mean difference not adjusted
for potential confounders/
single apoC-III measurement
after outcome occurred
Wiseman
et al, 199134
UK Retrospective
case–control
study
96 35 N/A 44.6 6 5.8 73 Plasma apoC-III AP, MI Cases and
controls, PMH
Comparison of mean difference
not adjusted for potential
confounders/single apoC-III
measurement after outcome
occurred/generalizability:
only included CV events in
patients younger than 50 y
Luc et al,
199635
France Retrospective
case–control
study
849 360 N/A NR 100 Plasma apoC-III,
non-HDL apoC-III,
HDL apoC-III,
apoC-III ratio†
MI Cases, WHO
criteria,
controls, NR
Ambiguous ascertainment of
end point*/single apoC-III
measurement after outcome
occurred/limited adjustment
for potential confounders
Sacks et al,
200020
USA, Canada Prospective
case–control
study
788 418 5 y 60 6 10 87 Non-HDL apoC-III
(quintiles), HDL
apoC-III (quintiles)
Recurrent MI,
coronary
death
Cases and
controls, WHO
criteria
Limited generalizability of
results due to study
population and assessment
of recurrent MI but not
first MI/measurement of
apoC-III at baseline only
Roselli della
Rovere
et al, 200333
Italy Prospective
cohort study
113 22 9 y 66.9 6 9.9 44 Plasma apoC-III AP, MI, stroke AP, EKG,
MI, WHO
criteria,
stroke, CT
Composite end point
including soft end point
(AP)/comparison of mean
difference not adjusted
for potential confounders/
single apoC-III measurement
at baseline
Onat et al,
200323
Turkey Retrospective
case–control
study
857 94 12 y 51.5 6 11.7 46 Serum apoC-III,
non-HDL apoC-III,
HDL apoC-III
CAD AP, PMH,
MI, EKG, or
myocardial
revascularization
Single apoC-III measurement
after outcome occurred/
exposure missing in 22%
of subjects/degree of
adjustment for confounders
limited and different for
males and females/ambiguous
ascertainment of a soft end
point (AP)
Scheffer et al,
200824
The Netherlands Prospective
cohort study
2244 231 15 y 61.4 6 7.3 46 Plasma apoC-III Cardiovascular
mortality
Cardiovascular
mortality (ICD-9
390–459) or
sudden death
(ICD 798)
Single apoC-III measurement
at baseline
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Gerber et al,
200325
Israel Retrospective
case–control
study
299 90 N/A 59.7 6 7.2 81 Serum apoC-III,
non-HDL apoC-III,
HDL apoC-III,
apoC-III ratio†
MI, CAD MI, NR,
CAD, PTCA or
CABG,
controls,
exercise test
(Bruce protocol)
Single apoC-III measurement
after outcome occurred/
ambiguous ascertainment
of end point/limited
adjustment for potential
confounders
Olivieri et al,
201022,‡
Italy Prospective
cohort study
633 64 57 mo 60.2 6 9.4 82 Serum apoC-III Cardiovascular
mortality
Death
certificates
listing CAD,
CHF, PAD, or
CVD
Limitations in statistical
analysis including limited
adjustment for confounders/
measurement of apoC-III
at baseline only
Mendivil et al,
201121
USA Prospective
case–control
study
1476 739 10 and
14 y‡
62.3 6 7.1 57 Plasma apoC-III,
non-HDL apoC-III
MI, coronary
death
WHO criteria
autopsy records
Single apoC-III measurement
at baseline
Jensen et al,
201232
USA Prospective
case–control
study
1271 634 10 and
14 y‡
62.5 6 7.6 55 HDL apoC-III MI, coronary
death
WHO criteria
autopsy records
Single apoC-III measurement
at baseline
Framingham
Heart Study42
USA Prospective
cohort study
2913 303 14 y 37.7 6 9.6 47 Plasma apoC-III AP, MI, CAD Framingham
Endpoint
Review
Committee
Single apoC-III measurement
at baseline
Verona Heart
Study42,‡
Italy Prospective
cohort study
794 92 59 mo 60.2 6 8.9 82 Plasma apoC-III Cardiovascular
mortality
Death
certificates
listing CAD,
CHF, PAD, or
CVD
Single apoC-III measurement
at baseline
ABI, ankle-brachial index; AP, angina pectoris; CA, coronary angiography; CABG, coronary artery bypass graft surgery; CAD, coronary heart disease; CHF, congestive heart failure; CT, computed tomography;
CVD, cerebrovascular disease; EKG, electrocardiogram; HDL, high-density lipoprotein; ICD-9, ninth revision of the International Classification of Diseases; LDL, low-density lipoprotein; MI, myocardial
infarction; N/A, not applicable; NR, not reported; PAD, peripheral arterial disease; PMH, history and physical examination; PTCA, percutaneous transluminal coronary angioplasty; US, duplex/Doppler
ultrasound; VLDL, very low–density lipoprotein; WHO, World Health Organization.
Serum or plasma apoC-III 5 total serum or plasma apoC-III; non-HDL apoC-III 5 apoC-III on LDL and VLDL; HDL apoC-III 5 apoC-III on HDL.
*Ambiguous ascertainment of end point5 ascertainment of the outcome occurred by different criteria in subjects with or without CVD (eg, coronary angiography for cases and history taking for control) or
was not reported for either group.
†Ratio of: (HDL ApoC-III) over (non-HDL ApoC-III); 2 individual publications presumably using an overlapping cohort from the Verona Heart Study.
‡Data were obtained from 2 independent cohort studies (Nurses’ Health Study and Health Professionals Follow-Up Study) as a nested case–control study design.
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Table 2 ApoC-III levels in patients with and without cardiovascular disease as reported in original studies
Author, year,
reference Cardiovascular outcome
ApoC-III
measurement(s)
ApoC-III
concentration,
mg/dL without CVD
ApoC-III
concentration,
mg/dL, with CVD
Reported
P value
Genest et al, 199141 CAD Plasma ApoC-III 3.6 6 2.0 2.7 6 0.8 ,.001
Wiseman et al, 199134 CAD, stroke, PAD Plasma ApoC-III 10.3 6 3.1 16.6 6 5.7 NR
Luc et al, 199635 MI (French cohort) Plasma ApoC-III 2.92 6 1.12 2.93 6 1.12 NS
Non-HDL ApoC-III 0.93 6 0.59 1.03 6 0.54 .01
HDL ApoC-III 1.99 6 0.71 1.89 6 0.72 NS
MI (Irish cohort) Plasma ApoC-III 2.95 6 1.29 3.32 6 1.35 .005
Non-HDL ApoC-III 1.13 6 0.69 1.49 6 0.81 .02
HDL ApoC-III 1.82 6 0.78 1.82 6 0.66 NS
Sacks et al, 200020 Recurrent MI, coronary death Non-HDL ApoC-III 6.1 6 2.5 6.6 6 2.6 .007
HDL ApoC-III 5.3 6 1.8 5.5 6 2.0 .15
Roselli della Rovere
et al, 200333
AP, MI, stroke Plasma ApoC-III 11.1 6 4.5 9.0 6 3.6 ,.05
Onat et al, 200323 CAD (male) Serum ApoC-III NR NR NR
Non-HDL ApoC-III 6.32 6 NR 6.86 6 NR
HDL ApoC-III NR NR
CAD (female) Serum ApoC-III NR NR NR
Non-HDL ApoC-III 6.14 6 NR 7.16 6 NR
HDL ApoC-III NR NR
Scheffer et al, 200824 Cardiovascular mortality Plasma ApoC-III 9.89 6 NR 10.35 6 NR ,.01
Gerber et al, 200325 MI, CAD Serum ApoC-III 16.9 6 5.4 18.8 6 4.9 .003
Non-HDL ApoC-III 5.0 6 3.0 6.4 6 3.1 ,.001
HDL ApoC-III 5.5 6 2.0 5.1 6 2.4 .09
Olivieri et al, 201022 Cardiovascular mortality Serum ApoC-III 11.8 6 NR 12.9 6 NR .03
Mendivil et al, 201121 MI, coronary death (male) Plasma ApoC-III 16.0 6 9.0 17.0 6 9.0 .16
Non-HDL ApoC-III 5.2 6 1.75 5.9 6 2.05 ,.05
MI, coronary death (female) Plasma ApoC-III 16.0 6 10.0 18.0 6 11.0 .30
Non-HDL ApoC-III 4.5 6 1.9 5.4 6 2.45 ,.05
Jensen et al, 201232 MI, coronary death (male) HDL ApoC-III 11.0 6 8.0 12.0 6 10.0 NR
MI, coronary death (female) HDL ApoC-III 12.0 6 7.0 12.0 6 10.0 NR
AP, angina pectoris; CAD, coronary heart disease; CVD, cardiovascular disease; HDL, high-density lipoprotein; MI, myocardial infarction; NR, not
reported; NS, not significant; PAD, peripheral arterial disease.
Serum or plasma apoC-III 5 total serum or plasma apoC-III; non-HDL apoC-III 5 apoC-III on low-density lipoprotein and very low–density
lipoprotein; HDL apoC-III 5 apoC-III on HDL.
504 Journal of Clinical Lipidology, Vol 9, No 4, August 2015complications in the Netherlands (HOORN), Scheffer et al
found that plasma apoC-III concentration at baseline was
prospectively associated with cardiovascular mortality.24
The study population consisted of 2244 participants, aged
50 to 75 years, at baseline. In models only partially adjust-
ing for lipid risk factors along with age, gender, fasting
glucose, and glycohemoglobin, further adjustment for
TGs resulted in a statistically nonsignificant association of
apoC-III and cardiovascular mortality (1.50 [0.94–2.40]).
The fully adjusted model including TG levels plus many
traditional cardiovascular risk factors showed a hazard ratio
for cardiovascular death of 1.85 (1.02–3.38) between the
highest and the lowest quartile of plasma apoC-III.24
A report on apoC-III and cardiovascular risk by
Mendivil et al21 is again a nested prospective case–control
study. Using the Nurses Health Study in women and the
Health Professionals Follow-Up Study in men, the authors
assessed the incidence of nonfatal and fatal MI over 10 and14 years of follow-up, respectively. Comparing the highest
to the lowest quintile they report relative risk estimates for
apoC-III concentration in LDL of 1.97 (1.26, 3.06) and in
VLDL of 1.32 (0.88, 1.96). However, after adjustment
for TGs, the relative risk for apoC-III in LDL was not
significant: 1.33 (0.81–2.20). The association of total
plasma apoC-III with MI was a relative risk (RR) of 1.48
(0.96–2.28) and decreased to relative risk(s) 0.96 (0.60–
1.56) in a model that adjusted for TGs. Although this report
is also limited by a single measurement of apoC-III at the
beginning of a 5-year follow-up time, it is the largest study
in terms of numbers of individuals included in this review
and provides detailed statistical analysis with models
adjusting for a large number of confounders including TG
levels. The investigators found similar association of
apoC-III with MI in both their separate analyses for males
and females and in the combined analysis. Furthermore, the
behavior of effect estimates in males and females was
Table 3 Relative risk estimates for apoC-III and cardiovascular disease as reported in original studies
Author, year,
reference
Comparison for
risk estimate Outcome
Total serum or
plasma ApoC-III HDL ApoC-III Non-HDL ApoC-III Factors adjusted for
Sacks et al, 200020 5th vs 1st quintile Recurrent MI,
coronary death
— 1.28 (0.8–2.0) 2.25 (1.4–3.6) Age, sex, smoking, hypertension,
LVEF, LDL, HDL, triglycerides
Onat et al, 200323 4th vs 1st quartile CAD (men) 3.88 (1.32–11.4) 2.70 (1.0–7.25) 8.87 (2.64–29.8) Women: none; men: age, LDL-C
CAD (women) 2.54 (1.0–6.42) 2.57 (0.94–7.01) 3.22 (1.29–8.01)
Scheffer et al, 200824 4th vs 1st quartile Cardiovascular
mortality
1.85 (1.02–3.38) — — Age, sex, glucose, HDL, LDL,
triglycerides, BMI, waist/hip
ratio, BP, smoking
Gerber et al, 200325 1-SD difference MI, CAD 1.82 (1.18–2.79) 0.64 (0.42–0.96) 2.44 (1.58–3.78) Age, sex, cholesterol, LP(a),
hypertension, diabetes,
smoking, HDL
Mendivil et al, 201121 5th vs 1st quintile MI, coronary death 0.96 (0.60–1.56) — 1.33 (0.81–2.20) Age, smoking, FHx, hypertension,
alcohol, BMI, DM, triglycerides
Jensen et al, 201232 5th vs 1st quintile MI, coronary death — 1.42 (0.79–2.57) — Age, smoking, hypertension,
alcohol, BMI, postmenopausal
status, HRT, HDL
Framingham Heart
Study 201442
Per 1 mg/dL MI, AP, CAD 1.017 (0.99–1.05) — — Age, sex, smoking, hypertension
treatment, SBP, DBP, lipid-
lowering medication, DM, LDL,
HDL, fasting serum glucose
Verona Heart
Study 201442
Per 1 mg/dL Cardiovascular
mortality
1.09 (1.02–1.16) — — Age, sex, smoking, DM, LDL, HDL,
hypertension, lipid-lowering
medication, fasting serum glucose
AP, angina pectoris; BMI, body mass index; CAD, coronary artery disease; DBP, diastolic blood pressure; DM, diabetes mellitus; FHx, family history of MI before age 60 years; HDL, high-density lipoprotein;
HRT, hormone replacement therapy; LDL-C, low-density lipoprotein cholesterol; LVEF, left ventricular ejection fraction; MI, myocardial infarction; SD, standard deviation; SBP, systolic blood pressure.
Relative risks from 8 studies reporting estimates for total, HDL apoC-III, and/or non-HDL apoC-III are shown. Effect estimates from the main multivariable model with the greatest degree of adjustment for
confounders are listed along with the covariates of adjustment. HDL Apo-CIII 5 apoC-III on HDL and non-HDL apoC-III 5 apoC-III on LDL and very low–density lipoprotein.
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Figure 2 Standardized mean differences in total plasma and non-HDL and HDL apoC-III between subjects with and without cardiovas-
cular disease (CVD). Pooled effects were calculated for (A) total plasma apoC-III, (B) non-HDL apoC-III, and (C) HDL apoC-III. Three
studies (Luc et al; Mendivil et al; and Jensen et al) reported measurements from 2 cohorts as indicated. The difference was calculated as
follows: blood concentration (without CVD) minus blood concentration (with CVD). Between-study heterogeneity was assessed by the
I2 statistic. CI, confidence interval; HDL, high-density lipoprotein; SMD, standardized mean difference.
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adjustment for confounders. With increasing adjustment,
the relative effect estimates were diminished as expected.
However, the most substantial decrease in effect size
occurred with adjustment for TGs resulting in a null-
association for total plasma apoC-III and apoC-III in
LDL. At the same time, the significant association between
the apoB concentration of LDL with apoC-III and MI per-
sisted in spite of adjustment for TGs.
Jensen et al using the same 2 prospective cohort samples
(Nurses Health Study and Health Professionals Follow-Up
Study) showed an association of HDL apoC-III and
cardiovascular events (nonfatal and fatal MI; RR, 1.42
[0.79, 2.57] for the 5th vs 1st quintiles of apoC-III
concentration in HDL).32
Finally, the TG and HDL Working Group of the Exome
Sequencing Project (National Heart, Lung, and Blood
Institute) published effect estimates for the association of
plasma apoC-III and cardiovascular events in 2 prospective
cohorts (Framingham Heart Study and Verona Heart
Study).42 Adjustment for confounders was extensive in
both cohorts, although not for TGs, and suggested noassociation of apoC-III with incident CHD (RR, 1.02
[0.99–1.05]; Framingham Heart Study) but a slightly
increased odds ratio for cardiovascular death in participants
with known CAD (odds ratio, 1.09 [1.02–1.16]; Verona
Heart Study).42
Meta-analysis of relative risk estimates
The relative risk estimates for total apoC-III,21–25
HDL apoC-III,20,23,25,32 and non-HDL apoC-III20,21,23,25
were each pooled using statistical meta-analysis. Forest
plots are shown in Figure 3. Both total plasma apoC-
III (RR, 1.33 [1.06–1.66], P , .012) and non-HDL
apoC-III (RR, 2.48 [1.42–4.32], P 5 .001) demonstrated
a significantly increased risk of a cardiovascular event
with higher levels of apoC-III. The degree of heterogene-
ity in this analysis was moderate but nonsignificant both
for total plasma apoC-III (I2, 51%, P 5 .068) and non-
HDL apoC-III (I2, 34.8%, P 5 .203). All studies consis-
tently showed an increased risk for cardiovascular events
with higher plasma levels of either total plasma apoC-III
or non-HDL apoC-III.
Figure 3 Relative risk estimates for (A) total plasma, (B) non-HDL apoC-III, (C) HDL apoC-III, and (D) HDL apoC-III (excluding one
retrospective study). Dose-response meta-analyses were performed using Generalized Least Squares for trend estimation of summarized
dose-response data (glst, STATA) and effect estimates were calculated for a 5-mg/dL increase in apoC-III. Pooled effect sizes for a 5-
mg/dL apoC-III increase were calculated using D 1 L random-effects models. Forest plots are shown for the association of total plasma
apoC-III, HDL apoC-III or non-HDL apoC-III, and cardiovascular events. Between-study heterogeneity was assessed by the I2 statistic. For
HDL apoC-III, a sensitivity analysis was conducted excluding one retrospective study that was responsible for the significant heterogeneity
test. CI, confidence interval; CV, cardiovascular; HDL, high-density lipoprotein.
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suggested a nonsignificant trend toward a protective effect
of apoC-III (RR, 0.73 [0.32–1.66], P 5 .454).20,23,25,32 Of
the 4 studies investigating this association 3 showed an
increased risk of CVD with increasing HDL apoC-III
levels,20,23,32 whereas one study suggested an inverse asso-
ciation.25 The one study causing substantial heterogeneity
(I2 73.3, P 5 .011) had several distinct limitations. The
most notable were the timing of assessment of exposure
and outcome, use of soft end points for CVD, and limited
adjustment for confounders in the analysis. In a sensitivity
meta-analysis excluding this study, the heterogeneity disap-
peared completely (I2 0%, P 5 .98); although the associa-
tion with cardiovascular risk turned positive, the effect
size remained rather small and did not reach statistical sig-
nificance in this analysis (RR, 1.09 [0.65–1.82]).
Discussion
In this systematic review, we summarized the current
literature on the association of apoC-III and cardiovascularevents including incident CAD or MI,20,21,23,25,32–35,41 cor-
onary death,20,21,32 stroke,33 or cardiovascular mortal-
ity22,24 through March 2014. It comprises 12 reports
including 5 retrospective case–control,23,25,34,35,41 3 pro-
spective nested case–control,20,21,32 and 4 prospective
cohort studies.22,24,33,42 Four of 11 studies used a study
design and analysis without computation of relative effect
estimates for the association of apoC-III and cardiovascular
events.33–35,41 The remaining studies published relative
risk estimates for one or more apoC-III fraction and cardio-
vascular risk with increasing apoC-III levels.20–25,32 In
these studies, total plasma apoC-III was associated with a
pooled average relative risks of 1.33 in 6 studies for an in-
crease of 5 mg/dL.21,23–26 Non-HDL apoC-III showed an
even stronger association with cardiovascular events with
a pooled relative risk of 2.48 in 4 studies.20,21,23,25 The ef-
fect estimates from the dose–response meta-analysis for
CVD in 4 studies comparing increasing HDL apoC-III
levels were quantitatively and qualitatively heterogeneous
ranging from RR of 0.35 to 1.26 per 5-mg/dL increase
(pooled RR estimate, 0.73).20,23,25,32 Only 2 of these studies
508 Journal of Clinical Lipidology, Vol 9, No 4, August 2015were prospective and adjusted for major cardiovascular risk
factors and demonstrated an RR of 1.06 and 1.26, respec-
tively, per 5-mg/dL increase in HDL apoC-III.20,32
There is growing evidence indicating a specific role of
apoC-III in atherosclerosis, lipid metabolism, and other
body systems that impact on cardiovascular risk.6,43–45
ApoC-III has been shown to impair plasma lipoprotein
metabolism and lead to hypertriglyceridemia.3–9,11 Besides
these effects, apoC-III is directly involved in stimulation of
vascular inflammatory processes.16–18 Because of its multi-
ple atherogenic functions, apoC-III may potentially be
a novel preventive and therapeutic target in fighting
CVD.44,45 In this context, blacks have shown an attenuated
dietary response of apoC-III suggesting that healthy diets
that lower lipoproteins containing apoC-III may be more
effective in whites than in blacks.46 An antisense drug is
being developed that specifically inhibits hepatic apoC-III
synthesis and that substantially lowers apoC-III and TG
levels in patients with hypertriglyceridemia.37
To this date, several methodologically sound clinical
studies have been conducted to examine the association of
apoC-III with cardiovascular events and were included in
this meta-analysis.20–25,32–35,41 ApoC-III exists on both
apoB-containing and apoAI-containing lipoproteins,
respectively, but is not essential to the basic lipoprotein
particle structure in either case. Thus, a variety of
different apoC-III fractions (ie, total plasma apoC-III,
non-HDL apoC-III, and HDL apoC-III) have been stud-
ied,20–25,32–35,41 but so far, there is no obvious consensus
as to what is the most important apoC-III fraction to be
measured from a standpoint of cardiovascular risk assess-
ment. Conclusions about the different apoC-III fractions
are limited given the quantitative and qualitative differ-
ences in effect estimates reported in the studies and sum-
marized here (Tables 2 and 3). Nonetheless, our data
clearly indicate that the apoC-III fraction found on LDL
and VLDL (non-HDL apoC-III) and total plasma
apoC-III are significantly associated with an increased
risk for cardiovascular events. Moreover, non-HDL
apoC-III may be of greater significance than total plasma
apoC-III. Studies investigating the association of HDL
apoC-III are inconsistent with 3 of 4 studies demon-
strating a positive association of cardiovascular events
with higher apoC-III levels.20,23,32 A fourth study differed
substantially and reported a protective association of HDL
apoC-III.25 Given some methodological limitations of this
study (Table 1), we elected to conduct a sensitivity anal-
ysis excluding said study. Although this resolved the issue
of heterogeneity and resulted in a positive association of
HDL apoC-III and CVD, the pooled relative risk
remained small and did not reach statistical significance.
Thus, in the current setting of a controversial debate on
the role of HDL in CVD, more prospective studies are
needed to investigate HDL apoC-III as a predictor of car-
diovascular risk.
The presented meta-analysis has important limitations
that need to be taken into consideration when interpretingthe results. There were only a small number of studies
available for inclusion in this meta-analysis, resulting in
limited statistical power and limiting potentially important
subgroup analyses (for example, differentiation by study
design). Several important limitations in study conduct or
analysis must be considered for some of the currently
available reports (Table 1). In addition, the effect of
apoC-III on the metabolism of TG-rich lipoproteins com-
plicates the interpretation of risk estimates for apoC-III
that are adjusted for TGs. As a result, models assessing
the association of apoC-III with CVD with and without
adjustment for TGs are of particular interest. Of the
included studies, only few reported risk estimates for
apoC-III after adjustment for TG levels.20,21,24 Thereof, 2
well-conducted, large, prospective studies resulted in some-
what different conclusions.21,24 The results of Mendivil
et al suggest that variation in TG levels accounts for the
risk increase observed for higher levels of total apoC-III,
whereas Scheffer et al report a consistent association
even after adjustment for TG levels.21,24 Thus, it remains
to be demonstrated to what extent apoC-III is a TG-
independent risk factor for cardiovascular events and could
not be evaluated in this meta-analysis given the sparse data.
In conclusion, our meta-analysis provides evidence for
an association of cardiovascular events with blood apoC-III
level in total plasma or in VLDL and LDL. More data are
needed to determine importance of levels of apoC-III in
HDL for cardiovascular risk management and to elucidate
the interaction between TGs and apoC-III in relation to risk
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